Drug Deficit Turning India’s Claris Into Target: Real M&A

Claris Lifesciences Ltd. may be the next takeover target among Indian injectable-drug producers as a shortage of medicines in the U.S. prompts buyers to seek companies with approved manufacturing facilities.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.